GlassScriptPhysician profile
Qiang Nai
NPI 1194105312
$2,566.61
in general payments reported to CMS, 2019-2025
37 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2022: $106 · 2024: $709 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $219.21 | 2022-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $196.85 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $145.12 | 2019-2024 | Opdualag |
| Janssen Biotech, INC. | $137.31 | 2024-2025 | Rybrevant, Darzalex, Talvey |
| Incyte Corporation | $124.96 | 2024-2025 | Jakafi |
| Emd Serono, INC. | $99.72 | 2024-2025 | |
| Genentech USA, INC. | $97.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $87.93 | 2025 | Libtayo |
| Sobi, INC | $86.77 | 2024-2025 | |
| Genzyme Corporation | $84.89 | 2025 | |
| Abbvie INC. | $83.89 | 2025 | |
| Gilead Sciences, INC. | $78.67 | 2025 | Trodelvy |
| Geron Corporation | $77.61 | 2025 | Rytelo |
| Pfizer INC. | $76.74 | 2024-2025 | |
| Glaxosmithkline, LLC. | $72.07 | 2024-2025 | Jemperli, Zejula, Ojjaara |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $66.18 | 2024-2025 | Illuccix |
| Karyopharm Therapeutics INC. | $62.79 | 2024-2025 | Xpovio |
| Agios Pharmaceuticals, INC. | $61.55 | 2025 | Pyrukynd |
| Exelixis INC. | $61.26 | 2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $58.13 | 2024-2025 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $53.14 | 2025 | Tagrisso |
| Daiichi Sankyo INC. | $50.88 | 2024-2025 | Datroway, Enhertu |
| Celgene Corporation | $49.78 | 2024 | Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $48.39 | 2025 | |
| Shield Therapeutics INC | $47.50 | 2024 | |
| Adc Therapeutics America, INC. | $45.59 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $45.06 | 2025 | Orgovyx |
| Array Biopharma INC | $44.23 | 2025 | Braftovi, Tukysa, Mektovi |
| Kite Pharma, INC. | $32.30 | 2025 | Yescarta |
| Invivyd INC | $28.53 | 2025 | Pemgarda |
| Stemline Therapeutics INC. | $28.35 | 2025 | Orserdu |
| Tempus Ai, INC | $23.06 | 2024 | |
| Eisai INC. | $20.97 | 2025 | |
| Novocure INC. | $17.91 | 2025 | Optune Lua (Novottf-200t) |
| Acrotech Biopharma INC. | $17.86 | 2025 | Beleodaq |
| Astellas Pharma US INC | $17.18 | 2024 | Xtandi |
| Iovance Biotherapeutics, INC. | $17.15 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qiang Nai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.